Mini-Mental State Examination (MMSE) Score Calculator

How to Use This Calculator

1. Enter scores for each of the 6 MMSE domains from the administered test.
2. Total score and severity classification appear instantly.
3. Domain Analysis tab: percentage performance per domain.
4. MMSE vs MoCA tab: compare classification across both tools.
5. Professional tier: age/education context, workup guidance, and ADL risk assessment.

Formula

Example

Frequently Asked Questions

• What is the MMSE and how was it developed? ▼
  The Mini-Mental State Examination (MMSE), also known as the Folstein test, is a 30-point cognitive screening instrument developed by Marshal Folstein, Susan Folstein, and Paul McHugh, first published in the Journal of Psychiatric Research in 1975. It was the first brief, standardized cognitive assessment tool and became the most widely used cognitive screening instrument in the world over the subsequent five decades. The MMSE assesses five cognitive domains across 11 items: orientation to time (5 points) and place (5 points), registration of three objects (3 points), attention and calculation (5 points via serial 7s or spelling WORLD backward), recall of the three previously registered objects (3 points), and language skills including naming (2 points), phrase repetition (1 point), a three-step command (3 points), reading and following a written instruction (1 point), writing a sentence (1 point), and copying a figure (1 point). Administration takes approximately 10 minutes by a clinician and requires no specialized training. The MMSE is copyrighted by Psychological Assessment Resources (PAR) — unlike the open-access MoCA — which has led some institutions to use the MoCA or other tools to avoid licensing costs.
• What MMSE score indicates dementia? ▼
  Dementia severity staging using the MMSE has been standardized based on decades of clinical research. Scores of 24–30 are generally considered normal; however, highly educated individuals may show significant cognitive decline while still scoring in this range due to high cognitive reserve. Scores of 18–23 indicate mild-to-moderate cognitive impairment, consistent with mild dementia — patients at this level may have difficulty with complex instrumental activities of daily living (IADLs) such as managing finances, medications, and driving. Scores of 10–17 indicate moderate-to-severe impairment, consistent with moderate dementia — supervision for most IADLs is required, and some basic ADLs may be affected. Scores below 10 indicate severe impairment and profound dementia, with dependence in most activities of daily living. These severity stages do not constitute a diagnosis of dementia, which requires both cognitive impairment and functional decline documented by history. Typical Alzheimer's disease causes MMSE decline at a rate of approximately 2–4 points per year, though decline accelerates as disease progresses. Vascular dementia may show stepwise decline rather than gradual progression. Important caveat: education and age significantly influence MMSE scores — an 85-year-old with 6 years of education may score 22–23 without dementia, while a 60-year-old physician scoring 24 may have significant disease. Age and education-stratified normative data should be applied when available.
• How does the MMSE compare to the MoCA for detecting early dementia? ▼
  The fundamental distinction between the MMSE and the Montreal Cognitive Assessment (MoCA) is their sensitivity for detecting mild cognitive impairment (MCI) — the transitional state between normal aging and clinical dementia that is the primary target of early intervention programs. A landmark comparison study by Nasreddine and colleagues (2005) found that the MMSE detected only 18% of MCI patients at a cut-point of 23/24, compared to 90% sensitivity for the MoCA at a cut-point of 25/26. This large difference in MCI sensitivity exists because the MMSE does not include tasks that are sensitive to early prefrontal and hippocampal dysfunction: it has no Trail Making B (executive function), no clock drawing (visuospatial-executive integration), no backward digit span (working memory), and limited verbal fluency assessment. The MMSE performs adequately for detecting established moderate-to-severe dementia (sensitivity 87–100% for established dementia) but is inappropriate as a screening tool when the clinical question is whether early-stage cognitive decline is present. For memory clinic evaluations, MCI workup, or research settings, the MoCA or a full neuropsychological battery is preferable. In nursing home and hospital settings where the clinical question is severity of established dementia rather than detection of early impairment, the MMSE remains widely used for its familiarity and available historical data.
• What factors can cause a falsely low MMSE score? ▼
  Numerous factors unrelated to underlying dementia can produce low MMSE scores, and clinicians must account for these when interpreting results. Educational attainment is the most significant confounder — individuals with fewer than 8 years of education score an average 3–5 points lower than educated peers on orientation and attention tasks, not because of cognitive impairment but due to unfamiliarity with the types of tasks assessed. Age itself is associated with declining scores; normative data show mean MMSE scores of approximately 28 at age 60, 27 at age 70, and 25 at age 80 in cognitively healthy individuals. Cultural and linguistic factors matter significantly — orientation questions about date and day of week may be less salient in some cultures; naming tasks may reflect cultural unfamiliarity rather than anomia. Acute medical illness, fever, metabolic encephalopathy, delirium, severe depression (pseudodementia), acute psychosis, anxiety during testing, severe sensory impairments (uncorrected visual or hearing deficits), physical disabilities affecting writing and drawing, and medication effects (heavy sedation, anticholinergics, opioids) can all substantially reduce MMSE scores without reflecting baseline cognitive ability. A single low score should never be used alone to diagnose dementia — repeat testing after treating reversible factors and comparison with informant history is essential.
• How is the MMSE used to guide Alzheimer's disease treatment decisions? ▼
  The MMSE has historically been used in regulatory approvals and clinical guidelines to define patient populations eligible for specific pharmacological treatments for Alzheimer's disease. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for mild-to-moderate AD, generally defined as MMSE 10–26 (some guidelines specify 10–23 for rivastigmine transdermal patch). For severe AD (MMSE < 10), memantine (an NMDA receptor antagonist) is approved in the US and Europe; donepezil 23 mg is also approved for severe AD based on the DOMINO trial. Combination therapy (donepezil + memantine) is approved in some countries for moderate-to-severe disease (MMSE 3–14). The newer anti-amyloid therapies (lecanemab, aducanumab) are indicated specifically for MCI and early-stage AD, often defined by amyloid PET or CSF biomarkers rather than MMSE alone. The MMSE remains valuable for longitudinal monitoring of treatment response — a sustained drop of 3 or more points per year despite treatment is often used as a threshold for reassessing treatment efficacy or advancing to higher-level care planning discussions. MMSE-guided care plans inform timing of driving cessation counseling, financial power of attorney discussions, and caregiver support program enrollment.

Related Calculators